亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases

医学 克拉斯 临床终点 内科学 临床试验 肿瘤科 肉瘤 不利影响 肺癌 临床研究阶段 癌症 队列 病理 结直肠癌
作者
Marcelo V. Negrão,Alexander I. Spira,Rebecca S. Heist,Pasi A. Jänne,Jose M. Pacheco,Jared Weiss,Shirish M. Gadgeel,Karen Velastegui,Wenjing Yang,Hirak Der‐Torossian,James G. Christensen,Joshua K. Sabari
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (28): 4472-4477 被引量:33
标识
DOI:10.1200/jco.23.00046
摘要

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Patients with Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated non-small-cell lung cancer (NSCLC) and untreated CNS metastases have a worse prognosis than similar patients without KRAS mutations. Adagrasib has previously demonstrated CNS penetration preclinically and cerebral spinal fluid penetration clinically. We evaluated adagrasib in patients with KRASG12C-mutated NSCLC and untreated CNS metastases from the KRYSTAL-1 trial (ClinicalTrials.gov identifier: NCT03785249; phase Ib cohort), in which adagrasib 600 mg was administered orally, twice daily. Study outcomes included the safety and clinical activity (intracranial [IC] and systemic) by blinded independent central review. Twenty-five patients with KRASG12C-mutated NSCLC and untreated CNS metastases were enrolled and evaluated (median follow-up, 13.7 months); 19 patients were radiographically evaluable for IC activity. Safety was consistent with previous reports of adagrasib, with grade 3 treatment-related adverse events (TRAEs) in 10 patients (40%) and one grade 4 (4%) and no grade 5 TRAEs. The most common CNS-specific TRAEs included dysgeusia (24%) and dizziness (20%). Adagrasib demonstrated an IC objective response rate of 42%, disease control rate of 90%, progression-free survival of 5.4 months, and median overall survival of 11.4 months. Adagrasib is the first KRASG12C inhibitor to prospectively demonstrate IC activity in patients with KRASG12C-mutated NSCLC and untreated CNS metastases, supporting further investigation in this population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
叶随风起完成签到,获得积分10
3秒前
勤劳三毒完成签到,获得积分10
4秒前
5秒前
baishier发布了新的文献求助10
6秒前
6秒前
BYL完成签到,获得积分10
7秒前
英俊的铭的应助被mitolin采纳,获得10
7秒前
大方碧完成签到,获得积分10
8秒前
眼睛大向薇完成签到 ,获得积分10
10秒前
巨型肥猫发布了新的文献求助10
10秒前
13秒前
幸运的风完成签到,获得积分10
13秒前
今天努力学习了吗完成签到,获得积分10
14秒前
15秒前
贤惠的诗柳完成签到,获得积分10
17秒前
whs完成签到,获得积分10
17秒前
天天快乐的应助被wise111采纳,获得10
17秒前
17秒前
Lucas的应助被www采纳,获得10
20秒前
隐形曼青的应助被行走的鱼采纳,获得10
20秒前
aveturner完成签到,获得积分10
22秒前
托伐普坦完成签到,获得积分10
25秒前
26秒前
27秒前
28秒前
梁益诚完成签到,获得积分10
28秒前
29秒前
baishier发布了新的文献求助10
31秒前
32秒前
wise111发布了新的文献求助10
33秒前
36秒前
D4C发布了新的文献求助10
41秒前
薄荷水完成签到,获得积分10
41秒前
王平安完成签到 ,获得积分10
42秒前
43秒前
行走的鱼发布了新的文献求助10
43秒前
hsyyk发布了新的文献求助10
43秒前
隐形曼青的应助被baishier采纳,获得10
46秒前
Leofar完成签到 ,获得积分10
46秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179656
求助须知:如何正确求助?哪些是违规求助? 9569921
关于积分的说明 21807706
捐赠科研通 7775141
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478778